CLINICAL STUDY RESULTS
A Study about Ravulizumab in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Not Previously Been Treated with a Complement Inhibitor
THANK YOU!
Alexion would like to thank all of the patients, their families, and caregivers who took part in this clinical study. Taking part in studies like this one contributes directly to the discovery of new medicines for atypical hemolytic uremic syndrome.
STUDY IDENTIFICATION INFORMATION
TREATMENT STUDIED: Ravulizumab, also known as ALXN1210 (trade name: Ultomiris®)
STUDY TITLE: Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
STUDY NUMBERS: Europe, 2016-002027-29 | United States, NCT02949128 | Protocol, ALXN1210-aHUS-311